$TPB

Turning Point Brands, Inc. (TPB): Results of Operations and Financial Condition

Turning Point Brands, Inc. (TPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_969512.htm EXHIBIT 99.1 ex_969512.htm Exhibit 99.1 Turning Point Brands Announces Second Quarter 2026 Results ● Q2 2026 Modern Oral Gross Revenue increased 149% to $87.0 million and Net Sales increased 128% to $68.4 million. Accounting for 48% of total company net sa

Original reporting
Published Aug 4, 2026, 12:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$TPB
Bullish
medium confidence
Mentioned
$TPB
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TPBBullishHigh
01

Why it matters

The most actionable update is the raised FY 2026 Modern Oral gross and net sales guidance, supported by triple-digit Modern Oral growth in Q2. However, profitability metrics (GAAP net income and adjusted EBITDA) declined sharply YoY, and SG&A rose materially, increasing execution risk.

02

Market read

Traders can update TPB positioning ahead of the scheduled earnings call based on the raised Modern Oral outlook and the disclosed profitability/mix tradeoffs.

03

What to watch

Gross profit growth is partly driven by a tariff refund and out-of-period COGS adjustments; traders should normalize margins and watch whether the Modern Oral mix sustains gross profit percentage (down to 56.9% from 62.5%).

Relevance 7/10Novelty 9/10Timing: pre-market today, filed Aug 4, 2026 with earnings call scheduled 9:00 a.m. ET

Background

SEC 8-K Item 2.02 with Exhibit 99.1 press release covering Turning Point Brands Q2 2026 financial results and FY 2026 outlook.

Company-level read

Ticker impact

$TPBBullishMedium confidence
Context

Turning Point Brands reports Q2 2026 results and raises FY 2026 Modern Oral gross and net sales guidance, with Modern Oral now 48% of net sales.

Expected impact

Likely near-term positive bias as traders reprice FY Modern Oral growth and margin trajectory, while monitoring the SG&A and adjusted EBITDA decline.

Evidence & confidence

The filing includes explicit Q2 datapoints (Modern Oral gross revenue +149%, net sales +128%) and a quantified FY 2026 outlook update (Modern Oral gross $330-$350m, net $260-$270m; Adjusted EBITDA $70-$90m). The negative GAAP/adjusted profitability trend adds uncertainty but does not negate the guidance upgrade.

Market effects

Signals demand shift toward modern oral nicotine products and potential margin/mix dynamics for alternative smoking accessory manufacturers.

Primarily US-focused retail distribution footprint (220,000 outlets in North America) may influence sentiment toward domestic consumer nicotine categories.

Limited direct global read-through; guidance is company-specific and tied to its product mix and tariff-related accounting.

Counterpoint

The guidance raise may be offset by structurally higher SG&A and freight costs, and adjusted EBITDA fell 50% YoY despite revenue growth.

Key entities

  • Turning Point Brands, Inc.

    Manufacturer and marketer/distributor of branded consumer products including alternative smoking accessories and consumables; subject of the 8-K.

  • Modern Oral

    Product category highlighted as the growth driver, with Q2 gross revenue +149% and FY 2026 guidance raised.

  • Stoker’s Products Segment

    Largest segment (75% of net sales in the quarter) with Q2 net sales +54.5% driven by Modern Oral.

  • Zig-Zag Products Segment

    Smaller segment (25% of net sales in the quarter) with Q2 net sales down 24.8% YoY.

Related articles

$TPBMedAI 9/10

Turning Point Brands Inc. (TPB): A Top Sin Stock to Buy On Growing Nicotine Pouch Opportunity

Turning Point Brands (NYSE:TPB) reported first-quarter results on May 7. Revenue rose 17% year over year to $124.3 million, driven by growth in its Modern Oral nicotine pouch segment. Gross profit increased 14.6% to $68.3 million, while adjusted EBITDA fell 6.5% to $25.9 million as margins contracted to 20.8%. The company said it is investing in sales, marketing, and manufacturing and targets double-digit market share by 2030.

$KDMed

Kyndryl Q1 Earnings Call Highlights

Kyndryl (NYSE:KD) Q1 call said demand is rising for AI deployment, hybrid modernization, cybersecurity and data-residency. It reported 40 deals worth over $50M in 12 months, with 10 in Q1, and Kyndryl Consult signings up 50%. IBM relationship changes are expected to weigh on constant-currency revenue through FY2027. FCF was -$401M; cash $2.1B. Outlook FY2027 reaffirmed.

$KAIMedAI 8/10

Kadant Q2 Earnings Call Highlights

Kadant (NYSE:KAI) reported Q2 equipment backlog of $182 million and said aftermarket demand stayed at record or near-record levels. Flow Control revenue rose 5% to $100 million; Industrial Processing revenue rose to a record $144 million; Material Handling bookings were $73 million. Q2 gross margin fell to 43.8%. Kadant raised FY revenue guidance to $1.19-$1.21B and adjusted EPS to $12.43-$12.68.

$KRPMed

Kimbell Royalty Q2 Earnings Call Highlights

Kimbell Royalty (NYSE:KRP) reported record Q2 adjusted EBITDA of $84.9 million, with cash G&A of $5.9 million ($2.50 per BOE). It declared a $0.47 per common unit cash distribution, up 15% QoQ, and said 47% may be return of capital. The borrowing base rose to $660 million; debt was $478.7 million. Rig activity and production varied by basin.

$KMPRMed

Kemper Q2 Earnings Call Highlights

Kemper (NYSE:KMPR) reported Q2 results and discussed credit-loss allowances tied to surplus notes in its reciprocal exchange, including a $21 million pre-tax charge on $36 million of notes. Holding-company liquidity was $766 million and debt-to-capital rose to 28.3%. Personal auto normalized combined ratio was 102% and commercial 93.7%, with California rate actions and restructuring savings over $80 million run-rate.

$KOPMed

Koppers Q2 Earnings Call Highlights

Koppers (NYSE:KOP) reported Q2 updates on capital spending of about $24M, shareholder returns of $47M, and debt reduction of $22M in the first half. Liquidity was $390M with net debt of $857M and net leverage at 3.5x. The board raised its dividend to $0.09/share. KOP kept 2026 sales guidance at $1.9B-$2.0B but cut adjusted EBITDA to $240M-$250M and EPS to $3.80-$4.20.